Menu Close

Trending

Bayer grabs Chinese okay for CKD therapy Kerendia
Novartis eyes earlier use of PD-1 drug in oesophageal cancer
A 3-step guide to addressing difficult issues and creating mutual solutions
AZ takes aim at BMS’ lead in neoadjuvant NSCLC
Blueprint cashes in on the past to build its future

Research and Development 2021

FUJIFILM Irvine Scientific’s COO on cell therapy, COVID vaccines and 50 years of the company

Deep Dive/ R&D/ Views & Analysis/ Views and analysis

Culture changes – FUJIFILM Irvine Scientific’s COO on cell therapy, COVID vaccines and 50 years of the company

, , , , , , 0 Comment

From animal processing, to cell therapy and AI, Tim Mullane, president, and chief operating officer tells pharmaphorum how

X
Culture changes – FUJIFILM Irvine Scientific’s COO on cell therapy, COVID vaccines and 50 years of the company
https://pharmaphorum.com/r-d/views-analysis-r-d/fujifilm-irvine-scientific-coo-cell-therapy-covid-vaccines/
LEO Pharmas new R&D lead on driving agility in drug development

Deep Dive/ R&D/ Views & Analysis/ Views and analysis

LEO Pharma’s new R&D lead on driving agility in drug development

, , , , , 0 Comment

After 27 years at Bayer, Jörg Möller has moved to LEO Pharma as the company’s EVP, global research

X
LEO Pharma’s new R&D lead on driving agility in drug development
https://pharmaphorum.com/r-d/views-analysis-r-d/leo-pharma-rd-lead-agility-drug-development/
Solving the information challenge of rare disease diagnosis

Deep Dive/ R&D/ Views & Analysis/ Views and analysis

Solving the “information challenge” of rare disease diagnosis

, , , , , 0 Comment

Getting a diagnosis is often the biggest challenge facing a rare disease patient in the UK. We take

X
Solving the “information challenge” of rare disease diagnosis
https://pharmaphorum.com/r-d/views-analysis-r-d/solving-the-information-challenge-of-rare-disease-diagnosis/
Centessas founder on the new companys unique R&D model

Deep Dive/ R&D/ Views & Analysis/ Views and analysis

Centessa’s founder on the new company’s unique R&D model

, , , , , 0 Comment

Putting together a quarter-billion dollar pharma company from ten mergers in four months is not for the faint-hearted

X
Centessa’s founder on the new company’s unique R&D model
https://pharmaphorum.com/r-d/views-analysis-r-d/centessa-founder-companys-unique-rd-model/
Inside the UK’s leading efforts to restart clinical research

Deep Dive/ R&D/ Views & Analysis/ Views and analysis

Inside the UK’s leading efforts to restart clinical research

, , , , , , , , 0 Comment

A herculean national effort has seen 69% of paused studies due to COVID restarted under the National Institute

X
Inside the UK’s leading efforts to restart clinical research
https://pharmaphorum.com/r-d/views-analysis-r-d/inside-uks-leading-efforts-restart-clinical-research/
Focus on Rare the invisible burden of rare diseases

Deep Dive/ R&D/ Views & Analysis/ Views and analysis

Focus on Rare: the invisible burden of rare diseases

, , , , , 0 Comment

Emma Sutcliffe from NexGen Healthcare Communications looks at how patient insights can bring the invisible challenges of living

X
Focus on Rare: the invisible burden of rare diseases
https://pharmaphorum.com/r-d/views-analysis-r-d/focus-on-rare-the-invisible-burden-of-rare-diseases/
The post-COVID face of pharma research and development

Deep Dive/ R&D/ Views & Analysis/ Views and analysis

The post-COVID face of pharma research and development

, , , , , 0 Comment

The acute phase of the COVID-19 pandemic not only brought delays, restrictions, and reconfigurations to pharmaceutical research &

X
The post-COVID face of pharma research and development
https://pharmaphorum.com/r-d/views-analysis-r-d/telemedicine-remote-site-visits-post-covid-pharma-rd/

Login

CONTINUE TO SITE >
X
Close in 10 seconds